IMPATH, Inc. [NASDAQ:  IMPH]

IMPATH operates a cancer information business.  The company characterizes malignant tissue by applying sophisticated analytical methods (e.g. immunohistochemistry; flow cytometry; molecular assay) to anatomic pathology, providing diagnostic and prognostic information to clinicians to enable them to manage their cases to achieve optimal clinical outcome.  IMPATH has been acquired by Genzyme.  More information is available at www.impath.com.  Headquarters: New York, NY.

 

ILEX Oncology, Inc. [NASDAQ:  ILXO]

ILEX specializes in drug therapy for malignant disease.  The company operates two businesses:  a drug development effort and a contract research organization (CRO). ILEX evolved from the Cancer Therapy and Research Center (CTRC) and its Institute for Drug Development.  It is affiliated with SWOG (SouthWest Oncology Group), and it has established a strategic relationship with Physicians Reliance Network (PRN).  ILEX has more than six compounds in various stages of clinical development.  Furthermore, it has several corporate relationships in place for its CRO business, including one with Eli Lilly.  ILEX has been acquired by Genzyme.  For more information, visit www.ilexoncology.com.  Headquarters: San Antonio, TX.

 

Gene Logic, Inc. [NASDAQ:  GLGC]

Gene Logic operates a functional genomics and bioinformatics business. The company determines patterns of differential gene expression utilizing a patented methodology known as READS^TM (Restriction Enzyme Analysis of Differentially Expressed Sequences).  READS^TM enables Gene Logic to identify and quantify expression levels of specific genes which are relevant to specific disease processes. The company maintains several databases containing proprietary information which it sells to pharmaceutical companies.  This proprietary information is valuable to pharmaceutical companies because it enables them to identify and to prioritize novel disease targets thus enabling them to hasten the process of drug discovery and development.  Gene Logic has established collaborative partnerships with Procter & Gamble Pharmaceuticals, Japan Tobacco, N.V. Organon, and SmithKline Beecham.  More information is available at www.genelogic.com.  Headquarters: Gaithersburg, MD.

 

SunPharm Corporation [NASDAQ:  GELX]

SunPharm was acquired by GelTex in November 1999.  GelTex operated a drug development and marketing business which commercialized small molecular weight organic compounds arising from two distinct yet closely related classes of molecules:  polyamine analogs and metal chelators.  It was acquired by Genzyme.  For more information, visit www.geltex.com.  Headquarters:  Jacksonville, FL.

 

NOMOS Corporation [NASDAQ:  NASI]

NOMOS Corporation is a leading supplier of radiation therapy solutions in the fight against cancer.  The company offers a broad-based product line that includes a full range of oncology options -- from the most advanced intensity modulated radiation therapy (IMRT), to conventional 2-D and 3-D planning systems and support products.  The NOMOS system, consisting of hardware and software, allows varying degrees of radiation to be delivered to each part of the tumor while minimizing the radiation to surrounding tissue.  The system can be retrofitted to existing linear accelerators converting them to state-of-the-art machines.  NOMOS was acquired by North American Scientific.  Additional information is available at www.nomos.com.  Headquarters:  Cranberry Township, PA

 

Martek Biosciences Corp. [NASDAQ:  MATK]

Martek Biosciences is the market leader in developing, manufacturing and selling products derived from microalgae. Microalgae represent a biochemically rich and diverse kingdom of organisms that provide a source of novel products for diverse markets including foods, nutriceuticals, pharmaceuticals and medical diagnostics.  Martek's lead products, DHA and ARA nutritional oils for infant nutrition, are now being sold as infant formula ingredients in over 70 countries worldwide.  The Company's Neuromins DHA adult supplement line is sold in over 12,000 US health food and drug stores. In addition to nutritional products, Martek sells tools to the pharmaceutical and diagnostic industries that are useful in drug development and medical diagnostics. More information is available at www.martekbio.com. Headquarters: Columbia, MD

 

AirLogix Corporation

AirLogix is a disease management company specializing in respiratory disorders.  The company's clients are providers of managed care throughout the United States.  The professionally trained staff members of Airlogix furnish hands on care to their clients' patients who are afflicted with chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD).  The company delivers professional care to patients on an out-patient basis, principally in the patients' homes.  Services include patient assessment and education as well as advice and coaching on life style change and self-management.   AirLogix was acquired by Centene Corporation.  Additional information is available at www.airlogix.com.  Headquarters:  Dallas, TX.

 

Eximias Pharmaceutical Corp. [AMEX: YMI]

EXIMIAS Pharmaceutical Corporation focused on the acquisition, development and commercialization of unique oncology and infectious disease products. The company had three novel, late-stage products, THYMITAQ^® and ORATAQ^™ for oncology, and MACROTAC^™ for oncology and infectious disease.  THYMITAQ^®, the company’s flagship product, has been evaluated in a Phase III ETHECC^©  trial for the treatment of patients with unresectable liver cancer.  Eximias was acquired by YM Biosciences.  More information is available at www.ymbiosciences.com.  Headquarters: Berwyn, PA

 

Galt Associates, Inc.

Galt is a medical consulting and software company that has developed solutions in drug safety record keeping that are sold to pharmaceutical companies.  Drug safety is a key issue for the pharmaceutical industry and governmental regulatory bodies.  The Food and Drug Administration (FDA) in the US is mandating electronic interchanges between pharmaceutical companies and the FDA.  Galt software products enable this electronic interchange.  The company's consulting and software products combined reduce delays in the drug approval process and accelerate the time to peak market sales for new drugs. Galt already sells consulting and software to 16 of the 20 largest global drug companies. Galt was acquired by Cerner Corporation.  More information is available at www.galt-assoc.com.  Headquarters: Sterling, VA

 

Confluent Surgical, Inc.

Confluent Surgical is a medical device company that is developing, marketing, and selling products that address unmet needs relating to post-surgical adhesion prevention and tissue sealing.  Post-surgical adhesions are scar tissue that forms as a result of trauma during surgery. Tissue sealants are needed to control the leakage of fluids such as blood, cerebrospinal fluid, air, bowel contents, etc. from tissues when the use of conventional wound closure techniques such as sutures and staples are either not practical or ineffective.  Confluent Surgical's products for this $4 billion worldwide market are based on a proprietary technology platform of in-situ polymerized biomaterials. The company was acquired by US Surgical, a division of Tyco.  For more information, visit www.confluentsurgical.com. Headquarters: Waltham, MA